A recent study found changes in blood flow in the retina could explain why some migraine patients experience visual symptoms. The findings could represent a long-sought observable marker for migraines that doctors can use to aid in the clinical treatment of the condition.
While patients with migraines often experience symptoms such as pain around the eye, sensitivity to light, blind spots and visual blurring, the mechanisms behind those symptoms have not been well understood. UCLA Health researchers used a non-invasive imaging technique, known as optical coherence tomography angiography, or OCTA, to visualize changes in the retinal blood vessels of migraine patients both during and between migraine attacks. The imaging was performed on 37 migraine patients with aura symptoms, 30 migraine patients without aura symptoms and 20 healthy patients for a control group.
Researchers found that blood flow decreases in the retina during migraine attacks for both migraine patients with and without aura symptoms. However, patients with aura symptoms were found to have lower blood flow in certain areas of the retina compared to patients without aura symptoms. Additionally, asymmetrical blood flow in the retinas was also correlated with which side of the head that migraine patients experienced pain.
The findings could indicate why some patients experience visual symptoms and may represent a biomarker for migraine attacks .
The study was led by former UCLA Department of Neurology Clinical Instructor Dr. Katherine Podraza (now of the Hartford Healthcare Headache Center) and coauthored by former UCLA Health research scientist Nitin Bangera, UCLA Goldberg Migraine Program clinical research coordinator Akira Feliz and UCLA Goldberg Migraine Program Director Dr. Andrew Charles of the UCLA Department of Neurology . Read the study in Headache .
Headache The Journal of Head and Face Pain
Randomized controlled/clinical trial
People
Reduction in retinal microvascular perfusion during migraine attacks
30-Nov-2023
Katherine Podraza: Has received support from the Amgen Competitive Grant Program in Migraine Research. Nitin Bangera: Has received salary support from the Baldwin Foundation and has ownership interest in CADET NM Inc. Akira Feliz: None. Andrew Charles: Has received compensation as a consultant for Amgen, Eli Lilly, and Lundbeck.